The US Food and Drug Administration (FDA) has granted approval to Indian pharmaceutical company Strides' wholly-owned subsidiary Shasun for its Acteazolamide tablets, the company said on Wednesday.
The US health regulator has approved Acteazolamide tablets to be used to prevent and reduce the symptoms of altitude sickness.
In a BSE filing, the company said that the product was a generic version of Diamox tablets.
It has been indicated in the dosages of 125 mg and 250 mg. Strides said the product, to be launched immediately, will be marketed by Strides Pharma Inc in the US.
According to IMS sales data, the US market for Acteazolamide tablets is worth approximately USD53m.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval